Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TWINS: Withdrawal of Moderate Efficacy Disease-Modifying Therapies in Inactive Relapsing-Remitting Multiple Sclerosis Patients Aged 55 and Over
2024-513475-41-00Phase 3Authorised
- Sponsor
- Strasbourg University Hospital
- Start
- Aug 2024
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of interferon beta-1a, diroximel fumarate, dimethyl fumarate, interferon beta, teriflunomide and 1 more in multiple sclerosis (MS) (2 arms), sponsored by Strasbourg University Hospital. Primary endpoint: Time to first clinical and/or radiological disease activity. Planned start Aug 2024; status: authorised.
02
Drugs
interferon beta-1adiroximel fumaratedimethyl fumarateinterferon betateriflunomide
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2024-513475-41-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513475-41-00.